Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, long-term, subdermal, drug implants with its proprietary NanoPortal™ technology.
Vivani’s lead assets, NPM-115 and NPM-119, are miniature, six-month, GLP-1 (exenatide) implants under development for chronic weight management obesity and type 2 diabetes, respectively. NPM-115 and NPM-119 are designed to optimize GLP-1 therapy by addressing two main challenges in achieving the full potential benefits of this therapy, medication non-adherence and tolerability.